Functional Characterization of N297A, A Murine Surrogate for low-Fc Binding Anti-Human CD3 Antibodies

Several low- or non-FcR binding anti-human CD3 monoclonal antibodies have been under investigation for the treatment of autoimmune diseases. To model the mechanism of action of these anti-human CD3 mAbs in the murine system, an Fc-modified anti-mouse CD3 antibody (N297A) was generated. N297A exhibited similar biological effects as Fc-modified anti-human CD3 antibodies including rapid, reversible reduction in peripheral leukocyte numbers, differential modulation of activated versus resting T cells, and reduced levels of induced cytokine release compared to the non-Fc-modified parent antibody. In an in vivo model of colitis induced by adoptive transfer of IL–10-deficient cells, administration of N297A significantly reduced body weight loss. As N297A shared many functional characteristics of non-FcR binding anti-human CD3 mAbs both in vitro and in vivo, it provides a means to model the mechanisms of action of Fc-modified anti-human CD3 antibodies in mouse.

• Publication year

  2009

• Venue

  Immunological Investigations

• Publication date

  2009-01-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1080/08820130802608238PMID 19172487PMCID 2646398
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antibodies, Fc receptors and cancer.

  2007cited by this paper
• Insulin Needs After CD3-Antibody Therapy in New-Onset Type 1 Diabetes

  2007influential reference
• A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis.

  2007cited by this paper
• Antibody treatment of ulcerative colitis

  2006cited by this paper
• Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+CD25−LAP+ T cells

  2006cited by this paper
• Modulation of antigen-specific T cell response by a non-mitogenic anti-CD3 antibody.

  2006cited by this paper
• A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease.

  2005cited by this paper
• Cutting Edge: CD8+CD122+ Regulatory T Cells Produce IL-10 to Suppress IFN-γ Production and Proliferation of CD8+ T Cells1

  2005cited by this paper
• Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

  2005cited by this paper
• TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs.

  2005influential reference
• IL-10-Producing CD4+CD25+ Regulatory T Cells Play a Critical Role in Granulocyte-Macrophage Colony-Stimulating Factor-Induced Suppression of Experimental Autoimmune Thyroiditis1

  2005cited by this paper
• A Single Course of Anti-CD3 Monoclonal Antibody hOKT3γ1(Ala-Ala) Results in Improvement in C-Peptide Responses and Clinical Parameters for at Least 2 Years after Onset of Type 1 Diabetes

  2005cited by this paper
• Lck Is Required for Activation-Induced T Cell Death after TCR Ligation with Partial Agonists1

  2004cited by this paper
• AgonistsCell Death after TCR Ligation with Partial Lck Is Required for Activation-Induced T

  2004cited by this paper
• IL-10 is involved in the suppression of experimental autoimmune encephalomyelitis by CD25+CD4+ regulatory T cells.

  2004cited by this paper
• Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).

  2003cited by this paper
• Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3γ1(Ala-Ala)

  2003cited by this paper
• A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease.

  2002influential reference
• Nuvion. Protein Design Labs.

  2002influential reference
• Novel therapeutics for the treatment of graft-versus-host disease

  2002influential reference
• Anti-CD3ε F(ab′)2 Prevents Graft-Versus-Host Disease by Selectively Depleting Donor T Cells Activated by Recipient Alloantigens1

  2001cited by this paper
• IgG Fc receptors.

  2001cited by this paper
• Anti-CD3 epsilon F(ab')2 prevents graft-versus-host disease by selectively depleting donor T cells activated by recipient alloantigens.

  2001cited by this paper
• Non-Fc Receptor-Binding Humanized Anti-CD3 Antibodies Induce Apoptosis of Activated Human T Cells1

  2000cited by this paper
• PHASE I TRIAL OF HuM291, A HUMANIZED ANTI-CD3 ANTIBODY, IN PATIENTS RECEIVING RENAL ALLOGRAFTS FROM LIVING DONORS1

  2000influential reference
• Enhancement of susceptibility to Fas-mediated apoptosis of TH1 cells by nonmitogenic anti-CD3epsilon F(ab')2.

  2000cited by this paper
• HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro.

  1999cited by this paper
• A humanized anti-CD3 antibody, HuM291, with low mitogenic activity, mediates complete and reversible T-cell depletion in chimpanzees.

  1999influential reference
• Humanized, nonmitogenic OKT3 antibody, huOKT3 gamma(Ala-Ala): initial clinical experience.

  1998cited by this paper
• Humanized, Nonmitogenic OKT3 Antibody, huOKT3γ(Ala-Ala): Initial Clinical Experience

  1998cited by this paper
• Human IgG2 variants of chimeric anti-CD3 are nonmitogenic to T cells.

  1997cited by this paper
• T helper cell 1-type CD4+ T cells, but not B cells, mediate colitis in interleukin 10-deficient mice

  1996cited by this paper
• Fc receptor binding of anti‐CD3 monoclonal antibodies is not essential for immunosuppression, but triggers cytokine‐related side effects

  1995cited by this paper
• An anti-murine CD3 monoclonal antibody with a low affinity for Fc gamma receptors suppresses transplantation responses while minimizing acute toxicity and immunogenicity.

  1995cited by this paper
• [Phase I study].

  1995cited by this paper
• Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review.

  1995cited by this paper
• Triggering via the alternative CD2 pathway induces apoptosis in activated human T lymphocytes

  1993cited by this paper
• Treatment of aGVHD with OKT3: clinical outcome and side-effects associated with release of TNF alpha.

  1991cited by this paper
• Cytokine release syndrome induced by the 145-2C11 anti-CD3 monoclonal antibody in mice: prevention by high doses of methylprednisolone.

  1991cited by this paper
• Cytokine‐related syndrome following injection of anti‐CD3 monoclonal antibody: Further evidence for transient in vivo T cell activation

  1990cited by this paper
• Complications and monitoring of OKT3 therapy.

  1988cited by this paper

• Effector functions are required for broad and potent protection of neonatal mice with antibodies targeting HSV glycoprotein D

  2024cites this paper
• Heterodimerization of T cell engaging bispecific antibodies to enhance specificity against pancreatic ductal adenocarcinoma

  2024cites this paper
• Antibody effector functions are required for broad and potent protection of neonates from herpes simplex virus infection

  2023cites this paper
• Human Antibodies for Viral Infections.

  2022cites this paper
• Potent SARS-CoV-2 neutralizing antibodies with therapeutic effects in two animal models

  2022cites this paper
• Fc-modified SARS-CoV-2 neutralizing antibodies with therapeutic effects in two animal models

  2022cites this paper
• CLEC5a-directed bispecific antibody for effective cellular phagocytosis

  2022cites this paper
• T Cell Bispecific Antibodies: An Antibody-Based Delivery System for Inducing Antitumor Immunity

  2021cites this paper
• Antibody engineering and its therapeutic applications

  2021cites this paper
• Thematic 2019 Letter from the Editor

  2019cites this paper
• Gene delivery of a modified antibody to Aβ reduces progression of murine Alzheimer’s disease

  2019cites this paper
• Silencing Fc Domains in T cell–Engaging Bispecific Antibodies Improves T-cell Trafficking and Antitumor Potency

  2019cites this paper
• A Site of Vulnerability on the Influenza Virus Hemagglutinin Head Domain Trimer Interface.

  2019cites this paper
• A bispecific antibody strategy to target multiple type 2 cytokines in asthma

  2018cites this paper
• Engineering multi-specific antibodies against HIV-1

  2018cites this paper
• Development of Novel Promiscuous Anti-Chemokine Peptibodies for Treating Autoimmunity and Inflammation

  2017cites this paper
• An "Fc-Silenced" IgG1 Format With Extended Half-Life Designed for Improved Stability.

  2017cites this paper
• Dual Roles for Regulatory T-cell Depletion and Costimulatory Signaling in Agonistic GITR Targeting for Tumor Immunotherapy.

  2017cites this paper
• Fc Engineering to Improve the Function of Therapeutic Antibodies.

  2016cites this paper
• Intraperitoneal Immunization with Cry1Ac Protoxin from Bacillus thuringiensis Provokes Upregulation of Fc‐Gamma‐II/and Fc‐Gamma‐III Receptors Associated with IgG in the Intestinal Epithelium of Mice

  2015cites this paper
• Highly reduced binding to high and low affinity mouse Fc gamma receptors by L234A/L235A and N297A Fc mutations engineered into mouse IgG2a.

  2015cites this paper
• Novel CD3‐specific antibody induces immunosuppression via impaired phosphorylation of LAT and PLCγ1 following T‐cell stimulation

  2014cites this paper
• Engagement of immune effector cells by trastuzumab induces HER2/ERBB2 downregulation in cancer cells through STAT1 activation

  2014cites this paper
• Characterization of a surrogate murine antibody to model anti-human CD3 therapies

  2013cites this paper
• Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies

  2013cites this paper
• Long term amelioration of established collagen-induced arthritis achieved with short term therapy combining anti-CD3 and anti-TNF treatments

  2012cites this paper
• Developmental immunotoxicity (DIT) testing of pharmaceuticals: Current practices, state of the science, knowledge gaps, and recommendations

  2012cites this paper
• Increased rheumatoid factor interference observed during immunogenicity assessment of an Fc-engineered therapeutic antibody.

  2011cites this paper
• Translational Pharmacokinetics and Pharmacodynamics of an FcRn‐Variant Anti‐CD4 Monoclonal Antibody From Preclinical Model to Phase I Study

  2011cites this paper
• MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a Phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments

  2011cites this paper
• Recent advances in the understanding of drug-mediated infusion reactions and cytokine release syndrome.

  2010cites this paper
• Dissociation of efficacy and cytokine release mediated by an Fc-modified anti-CD3 mAb in a chronic experimental autoimmune encephalomyelitis model.

  2009cites this paper